Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
$7.86
-3.0%
$9.73
$5.01
$12.75
$486.85M2.48694,209 shs1.49 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.13
+0.4%
$17.94
$4.18
$18.31
$2.73B1.171.70 million shs116,525 shs
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$1.54
-1.3%
$1.57
$0.60
$4.69
$128.53M1.271.47 million shs2.39 million shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$6.56
-6.2%
$4.10
$1.82
$8.75
$329.05M0.92121,271 shs189,216 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$40.10
+1.5%
$44.12
$27.99
$50.99
$3.02B1.15399,092 shs255,970 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-2.96%-6.65%-15.57%-26.47%-3.79%
MorphoSys AG stock logo
MOR
MorphoSys
+0.44%+0.44%-0.28%+57.38%+251.36%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
0.00%0.00%-0.65%+3.36%-62.62%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-6.15%+8.43%+106.29%+83.24%+45.45%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+1.52%-0.52%-6.00%-12.14%+1.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
1.2886 of 5 stars
3.51.00.00.02.41.70.0
MorphoSys AG stock logo
MOR
MorphoSys
0.669 of 5 stars
1.25.00.00.03.00.00.6
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
4.0317 of 5 stars
3.03.00.04.70.03.31.3
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
1.5711 of 5 stars
3.52.00.00.01.11.70.6
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
2.6098 of 5 stars
3.54.00.00.02.42.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
3.00
Buy$47.40503.05% Upside
MorphoSys AG stock logo
MOR
MorphoSys
2.38
Hold$11.78-35.02% Downside
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
2.00
Hold$3.68139.18% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$11.5075.30% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$59.4448.24% Upside

Current Analyst Ratings

Latest XENE, CMPS, RANI, MOR, and NGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
4/12/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$62.00
4/10/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
4/1/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$30.00
3/27/2024
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $9.00
3/25/2024
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
3/14/2024
MorphoSys AG stock logo
MOR
MorphoSys
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$17.00 ➝ $18.25
3/12/2024
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
3/1/2024
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $55.00
3/1/2024
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$46.00 ➝ $51.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/A$3.65 per shareN/A
MorphoSys AG stock logo
MOR
MorphoSys
$257.89M10.59N/AN/A$0.35 per share51.80
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
$4.42M29.10N/AN/A$1.80 per share0.86
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$2.72M120.97N/AN/A$0.51 per share12.86
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M320.76N/AN/A$14.18 per share2.83

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$118.46M-$2.39N/AN/AN/AN/A-58.72%-49.46%5/9/2024 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$1.56N/AN/AN/A-80.07%-694.31%-8.96%5/1/2024 (Estimated)
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%5/2/2024 (Estimated)
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$33.97M-$1.33N/AN/AN/AN/A-79.92%-44.08%5/8/2024 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$182.39M-$2.72N/AN/AN/AN/A-25.18%-23.99%5/14/2024 (Estimated)

Latest XENE, CMPS, RANI, MOR, and NGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2024Q4 2023
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.31-$0.27+$0.04-$0.27N/AN/A
3/13/2024Q4 2023
MorphoSys AG stock logo
MOR
MorphoSys
-$0.92$0.33+$1.25$0.33$76.30 million$63.53 million
3/11/2024Q4 2023
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
-$0.37-$0.33+$0.04-$0.33$2.00 million$0.17 million
2/29/2024Q4 2023
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
-$0.37-$0.53-$0.16-$0.53N/AN/A
2/29/2024Q4 2023
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.76-$0.64+$0.12-$0.64$2.30 millionN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
0.14
13.33
13.33
MorphoSys AG stock logo
MOR
MorphoSys
4.98
3.08
2.84
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
N/A
7.79
7.79
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
0.96
6.36
6.36
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
23.65
23.65

Ownership

Institutional Ownership

CompanyInstitutional Ownership
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
46.19%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
75.74%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
COMPASS Pathways plc stock logo
CMPS
COMPASS Pathways
18661.94 million59.31 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
524150.62 million150.55 millionNot Optionable
NGM Biopharmaceuticals, Inc. stock logo
NGM
NGM Biopharmaceuticals
13883.46 million53.50 millionOptionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
14050.16 million25.07 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
25175.43 million71.34 millionOptionable

XENE, CMPS, RANI, MOR, and NGM Headlines

SourceHeadline
Jennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Jennison Associates LLC Buys 352,573 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 25 at 7:27 AM
Federated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Federated Hermes Inc. Invests $15.96 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 23 at 5:35 AM
Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Investors Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)
americanbankingnews.com - April 18 at 3:04 AM
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
globenewswire.com - April 16 at 8:30 AM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by AnalystsXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by Analysts
americanbankingnews.com - April 16 at 2:34 AM
Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)
marketbeat.com - April 12 at 8:14 AM
Xenon Pharmaceuticals Inc (XENE)Xenon Pharmaceuticals Inc (XENE)
investing.com - April 10 at 12:10 PM
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
globenewswire.com - April 10 at 8:30 AM
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceXenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
globenewswire.com - April 4 at 4:01 PM
SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)SG Americas Securities LLC Sells 38,146 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 2 at 4:18 AM
Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. Sells 47,962 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
marketbeat.com - April 1 at 4:43 AM
Xenon Pharmaceuticals IncXenon Pharmaceuticals Inc
money.usnews.com - March 21 at 10:13 AM
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth PlansXenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - March 19 at 8:26 AM
XENE Apr 2024 47.500 putXENE Apr 2024 47.500 put
finance.yahoo.com - March 16 at 1:48 PM
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysXenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
globenewswire.com - March 12 at 4:01 PM
Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of StockInsider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) EVP Sells 7,137 Shares of Stock
insidertrades.com - March 11 at 6:41 AM
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
finance.yahoo.com - March 9 at 12:06 AM
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
globenewswire.com - March 5 at 4:01 PM
Buy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline ProgressBuy Rating Affirmed for Xenon Pharmaceuticals on Strong Neurological Pipeline Progress
markets.businessinsider.com - March 5 at 10:33 AM
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 2 at 2:52 PM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call TranscriptXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 2 at 9:52 AM
Xenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
finanznachrichten.de - March 1 at 2:30 PM
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in FocusXenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
zacks.com - March 1 at 9:36 AM
Buy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in NeuroscienceBuy Rating Justified by Xenon Pharmaceuticals’ Advanced Epilepsy Program and Growth Prospects in Neuroscience
markets.businessinsider.com - March 1 at 9:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

COMPASS Pathways logo

COMPASS Pathways

NASDAQ:CMPS
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
MorphoSys logo

MorphoSys

NASDAQ:MOR
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
NGM Biopharmaceuticals logo

NGM Biopharmaceuticals

NASDAQ:NGM
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Rani Therapeutics logo

Rani Therapeutics

NASDAQ:RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

NASDAQ:XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.